Introduction
Pediatric acute lymphoblastic leukemia (ALL) is the most common malignant disease in children [1] [2] [3] . ALL is a genetic disease resulting from accumulation of mutations of tumor suppressor genes and oncogenes [1] [2] [3] . Knowledge of these mutations can be of use for diagnosis, prognosis, and therapeutic clinical purposes, as well as, to provide an overall understanding of the pathogenesis of ALL [1] [2] [3] . Identification of mutated genes in ALL has evolved with improvement in technology. A recent approach is single nucleotide polymorphism (SNP) analysis using an array based technology 4, 5 that allows identification of amplifications, deletions and allelic imbalance, such as uniparental disomy [UPD, (represents the doubling of the abnormal allele due to somatic recombination or duplication and loss of the other normal allele)] [6] [7] [8] . However, since this technique detects allelic dosage, it cannot detect balanced translocations.
According to the HapMap publication, 9.2 million SNPs have been reported; and of these, 3.6 million have been validated 9 . Global genomic distribution of SNPs and its easy adaptability for high throughput analysis makes them the target of choice to look for genomic abnormalities in ALL and other cancers [5] [6] [7] .
Recently, higher resolution SNP-chip (50,000-500,000 probes) has been developed for large-scale SNP typing 4, 10 . With a large number of SNP-probes in combination with the algorithms specifically developed for copy number calculations, these SNP-chips enable genome-wide detection of copy number changes 11, 12 . The combination of SNP-chip technology, nucleotide sequencing, and bioinformatics allows the investigator to view the entire genome of ALL in an unbiased, comprehensive approach. Using SNP-chips, the chromosomal abnormalities can be evaluated at a very high resolution (molecular level: average distances of each probe are 47kb and 5.8kb in the50k/500k arrays, respectively 4, 10 ); and allele specific gene dosage level (gene dosage of paternal and maternal alleles) can be also analyzed in the whole genome 11, 12 . Hence, we name this new technology, "molecular allelokaryotyping" 12 .
In this study, we performed molecular allelokaryotyping on a very large cohort (399) of pediatric ALL samples to examine genomic abnormalities at high resolution. Further, we examined correlations between the genomic abnormalities detected by SNP-chip and clinical features including prognosis.
Methods

Clinical samples and DNA/RNA preparation
The ALL-BFM 2000 trial of the Berlin-Frankfurt-Münster (BFM) study group on treatment of childhood ALL enrolled patients from ages 1 to 18 years at diagnosis. Of the 566 patients (#299-#854), 399 patients representing 70 % of the entire patient population, had additional DNA available and could be included in the present SNP-chip study. The 167 patients not available for this analysis, did not differ from the 399 patients in this study with regard to their clinical and biological characteristics (data not shown).
Complete remission (CR) was defined as the absence of leukemia blasts in the peripheral blood and cerebrospinal fluid, less than 5% lymphoblasts in marrow aspiration smears, and no evidence of localized disease. At day 29, bone marrows were examined; and all patients in this SNP-chip analysis study obtained a CR at that time, the remission marrows were collected and used as matched control for the SNP-chip analysis.
Prednisone response was defined based on numbers of peripheral blood blasts per microliter on day 8; patients were classified into good (< 1000 blasts/microliter) and poor responders (≥ 1000 blasts/microliter) [13] [14] [15] . Relapse was defined as recurrence of lymphoblasts or localized leukemic infiltrates at any site.
DNA-index, immunophenotyping, molecular analysis of chromosomal abnormalities
Leukemic or normal bone marrow cells were stained with propidium iodide, and cellular DNA contents were measured by cytometric analysis as previously reported 16, 17 .
DNA-index was defined as the DNA content of leukemic cells compared wtith normal G0/G1 cells. When the DNA-index of leukemic cells was same as or greater than 1.16, it was defined as hyperdiploid ALL by DNA-index as previously reported 16, 17 .
Immunophenotyping of ALL was examined using anti-CD2, CD3, CD4, CD10, CD19, CD20, antibodies by FACS [13] [14] [15] . ETV6/RUNX1, BCR/ABL, and MLL/AF4 were examined by interphase FISH analysis using specific probes and by RT-PCR using specific primers for these fusion transcripts as described previously [13] [14] [15] .
Molecular allelokaryotyping of leukemic cells DNA from the 399 ALL samples as well as their paired normal DNA from remission samples were analyzed on Affymetrix® GeneChip® Human mapping 50K XbaI or 250K Nsp arrays (Affymetrix Japan, Tokyo, Japan) according to the manufacturer's protocol. Microarray data were analyzed for determination of both total and allelic-specific copy numbers using the CNAG program as previously described 11, 12 with minor modifications, only.
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where S i
A and S i B are the status of the ith sub-block (Si) in data A and B, respectively, and sum is taken for all sub-blocks. Clustering was initiated by finding a seed cluster of two samples showing the minimum distance and replacing them with the cluster data having the mean Si value of the two. This procedure was iteratively performed until all samples were converged to one cluster based on this distance using a program developed for this purpose (GNAGraph), which was followed by manual revisions focusing on particular genetic lesions selected by their frequencies within the sample set. CNAG and CNAGraph are available on request.
Quantitative genomic PCR (qPCR) and direct sequencing qPCR was performed on Real-time PCR machine, iCycler (Bio-Rad Laboratories, Hercules, CA) using iQ cyber-green supermix (Bio-Rad Laboratories) according to the manufacturer's protocol. Primer sequences used for the qPCR are listed in Supplement Table 2 . Gene dosage at the 2p allele was used as an internal control. Allelic gene dosage of 9p and 9q was measured, and these were compared with the levels in respective matched control DNA. SNP sites were amplified and directly sequenced on Autosequencer 3000 (Applied biosystems, Foster City, CA). Primers used for SNP site amplification are listed in Supplement Table 2 . Exons 12 and 14 of JAK2 gene were amplified as previously reported 18 . PCR products were purified and subjected to direct sequencing.
Data preparation
Proportional differences between groups were analyzed by either chi-squared (χ 2 ) or Fisher's exact tests. The Kaplan-Meier method was used to estimate survival rates. Differences were compared with the 2-sided log-rank test. Event-free survival was only.
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Results
Features of samples
Clinical features of 399 pediatric ALL patients are shown in Table 1 . Infant ALL (< 1years of age) were excluded from this study and 77 % (307 cases) of the patients were from one to nine year-old. Forty-nine cases of T-cell lineage ALL and 339 cases of B-cell lineage ALL were examined. Ninety-six samples (24 %) had ETV6/RUNX1 fusion and 6 cases had the BCR/ABL fusion gene.
Validation of SNP-chip data
Gene dosage, heterozygous SNPs, allele specific gene dosage and allelic composition [loss of heterozygosity (LOH)] was visualized as shown in Fig 1a using Table 2 ). Number of total chromosomes was counted manually in SNP-chip analysis; and ALL with more than 50 chromosomes was defined as HD-ALL by SNP-chip. When DNA-index of leukemic cells was same as or greater than 1.16, the sample was defined as HD-ALL by DNA-index 16, 17 . DNA-index of 278 ALL samples were available; and 200 cases were defined as non-HD ALL by both methods. SNP-chip detected more cases of HD-ALL (74 cases) than DNA-index. As shown in Figure 1a iv, SNP-chip can precisely detect gene dosage and this high sensitivity of SNP-chip analysis permitted more accurate detection of HD-ALL than by the DNA-index method. Results of these analyses validated that the abnormalities detected by SNP-chip were reliable.
Three common abnormalities in pediatric ALL Figure 2a summarizes molecular allelokaryotyping profiles of the 399 ALL cases after clustering with regard to the status of copy number alterations as well as copy number neutral LOH, so-called UPD, showing a number of clusters having common genetic lesions. Fig. 2b ). Concurrent abnormalities of p16Del and HD were rare (p <0.0001); concurrent abnormalities of ETV6Del and HD were also rare (p < 0.0001) (Fig. 2b) . No case had all three common abnormalities.
The clinical features of cases with each of these three genetic abnormalities were analyzed (Table 3) . Individuals with p16Del-ALL were more frequently older (p=0.017), had higher WBC (p<0.001), and T-cell lineage ALL (p<0.001). Those with ETV6Del-ALL were more often younger (p=0.009), non-T cell lineage (p=0.014), and ETV6/RUNX1 fusion gene positive (p<0.001). Patients having HD-ALL were more frequently younger (p<0.001), showed lower WBC (p <0.001), non-T cell lineage (p<0.001), and ETV6/RUNX1 negative (p<0.001).
Numerical chromosomal abnormalities in pediatric ALL
Numerical chromosome changes were frequently detected in pediatric ALL samples, as summarized in Figure 3a Small deletions that could not be detected by conventional cytogenetics were sensitively identified, including deletions of 3p14.2 (500kb), 3q26.32 (700kb) and Xp21.1 (1Mb) ( Table 4 and Supplementary Fig. 2 ). Non-random chromosomal abnormalities (frequency >1.5 % of all cases) are listed in Table 4 . Besides the three common genetic abnormalities, duplication of 1q (11 %) and deletion of 6q (11.5 %) were often detected. In 13 cases with 1q duplication, the duplication began at the PBX1 gene ( Fig. 2a and supplementary Fig. only.
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Recently, other groups of investigators performed SNP-chip analysis on pediatric ALL and found deletions of several transcriptional factors associated with B-cell development including PAX5 (9p13), EBF (5q33), Ikaros (7p12.2), Aiolos (17q12), LEF1(4q25), RAG1(11p12), and RAG2 (11p12) 19, 20 . We have also found deletion of these genes in our study. However, the frequency of deletion of these genes, except for PAX5, was low (less than 2 %) and/or the deleted regions contained multiple genes ( Table 4 , supplementary Fig. 2 and data not shown).
UPD
One of the major advantages of SNP-chip analysis is capability of sensitive detection of UPD, even in samples suffering from small tumor content; UPD in samples with as low as 20% of tumor contents are clearly identified (Fig. 1a iv) . Whole and partial chromosome UPDs were observed in 95 cases; 6 cases showed both whole and partial chromosome UPD (Fig. 3b) . Most of the whole chromosome UPD was detected in HD-ALL (Fig. 3c) . UPD of whole chromosome 9 was the most common whole chromosome UPD (Fig. 3b) . In contrast, UPD involving part of chromosomes was most often found in non-HD-ALL cases (Fig 3c) . Recurrent partial chromosome UPD was detected in many chromosomal regions (Fig. 3b) . We frequently found whole chromosome 9 UPD (18 cases) and 9p UPD (30 cases) (Fig. 3b) . INK4A deletion was often found in 9p UPD (23/30,77 %) while it was rare in whole chromosome 9 UPD (1/18, 6 %) (Fig. 3d) .
Relationship between genetic abnormalities Recurrent abnormalities described above were compared to each other (three common abnormalities and 26 non-random alterations) to detect relationships between these abnormalities (Supplementary Table 1 ). Strong correlations between abnormalities of 12p and 21q were detected; duplications of 12p and 21q often occurred simultaneously; duplications of 21q were accompanied by deletion of the ETV6 gene that was localized on 12p. ETV6Del ALL frequently had additional changes, including duplications (21q and 1q) and deletions (3p21, 1q, FHIT, 15q and 4q). Abnormalities involving chromosome X, including DMD (Xp21.2) deletion, were frequently accompanied by deletions of 8p, 4q and 6q. Deletion of 20q often occurred with either p16INK4A deletion or duplication of 21q ( Fig. 2a and Impact of non-random genetic abnormalities on prognosis.
We analyzed prognosis of cases showing non-random abnormalities listed in Table 4 and found that the recurrent abnormalities had no impact on the event-free survival (data not shown) except for amplification/duplication of chromosome 9q. Our initial, early analysis found that DFS of pediatric ALL patients was not impacted by ETV6 deletion either with or without ETV6/RUNX1. Nine cases with 9q amplification/duplication showed a poor prognosis (6 patients relapsed within 3 years) ( Supplementary Fig 3a) , although the number of cases having this abnormality is too small to reach a significant conclusion. Three of these cases also had duplication of part of chromosome 22 ( Supplementary Fig 3b) , suggesting that duplication of 9q is part of an extra copy of the Philadelphia chromosome. These three cases showed BCR/ABL positively by FISH/RT-PCR analysis (data not shown). Two other cases showed high copy number amplification that encompassed ABL and NUP214 genes ( Supplementary Fig 3c) , suggesting these cases had a NUP214/ABL fusion 21 . The ALL cells of these two cases were steroid-resistant and T-cell lineage phenotype.
Children with HD-ALL without gain of either chromosome 17 or 18 had a worse prognosis (Fig. 4) . Furthermore, children with HD-ALL and no extra copies of chromosomes 17 and 18 had a significantly worse prognosis (p=0.0003), with 53% event-free survival at 5 years compared to a 90% 5-year event-free survival in the other HD-ALL cohort (Fig. 4) .
Discussion
SNP-chip analysis is a reliable method to detect gene dosage which was validated by direct sequencing of SNP-sites and quantitative PCR in this study. To detect HD-ALL, DNA-index is not a sensitive method since contaminated normal cells (DNA-index 1.0) decrease the levels of DNA-index of hyperdiploid leukemic cells (greater than 1.0). Although karyotyping is a good method to detect HD-ALL, sufficient number of high-quality chromosomal metaphases is not always obtained from the leukemic cells. SNP-chip analysis may be a more useful and reliable method to detect this subtype of ALL.
Molecular allelokaryotyping of a large series of pediatric ALL samples showed three major abnormalities: deletion of p16INK4A, deletion of ETV6, and hyperdiploidy. Besides these three common abnormalities, a number of novel, non-random changes were found in ALL. Some of them showed a very narrow commonly deleted region which was limited to one target gene, including FHIT (3p14.2), TBL1XR1 (3q26.3), and DMD (Xp21.2). DMD is the causative gene for Duchenne type muscular dystrophy 22 . While only.
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inactivating mutations of this gene cause the disease, no association has been made between this disease and cancers, including ALL. Since DMD is an extremely large gene (2.4 Mb), deletion of it may occur as a result of instability of genomic DNA in ALL cells.
Other investigators and we have found in pediatric ALL a number of deleted genes,including transcriptional factors involved in B-cell differentiation 19, 20 . However, since no point mutations of those genes, except PAX5, were detected 19 , it is unclear that these transcriptional factors associated with B-cell development are target gene of these deletions. Mullighan et al. and we have found that PAX5 gene is frequently involved in deletions and translocations 19, 23 suggesting that impairment of PAX5 is associated with leukomogenesis. This study showed that numerical chromosomal changes and UPD were common genomic abnormalities in pediatric ALL. Interestingly, whereas trisomy 21 was the most common numerical chromosomal abnormality, UPD of chromosome 21 was not detected in our study. Even in 8 cases with Down syndrome who had trisomy 21 in their constitutional DNA, UPD of chromosome 21 was not detected. Although UPD of chromosome 21 in leukemic cells of patients with Down syndrome has been reported 8 , it may be a rare event in pediatric ALL. Chromosomal mis-segregation occurs when duplicated chromosomes separate improperly during cell division 24 , leading to numerical chromosomal changes in leukemic cells, including HD-ALL. Most of the whole chromosome UPD was detected in HD-ALL, suggesting that whole chromosome UPD is also due to chromosomal mis-segregation. In contrast, UPD involving part of chromosomes was most often found in non-HD-ALL cases. This may suggest that these partial UPDs are not caused by mis-segregation, but by mitotic recombination, which can usually cause chromosomal exchange 25 .
UPD involving chromosome 9 or 9p is a very common abnormality in pediatric ALL. INK4A gene may be a target gene of 9p UPD since most of the cases with 9p UPD had deletion of INK4A (23 of 30 cases with 9p UPD). For UPD involving whole chromosome 9, INK4A is not a target gene since only one case with whole chromosome 9 UPD had deletion of this gene (1/ 18, 6 %). What gene is the target of whole chromosome 9 UPD is unclear. Furthermore, 7 cases with 9p UPD had intact INK4A and the target gene of 9p UPD in these cases is also unknown. This is the first report showing that whole chromosome 9 UPD and 9p UPD are common abnormalities in pediatric ALL. Although Mullighan et al. also analyzed a large number of pediatric ALL patients by SNP-chip 19 , they did not report this abnormality." UPD on 9p is associated with activating point mutations of JAK2 in myeloproliferative disorders (MPD) [27] [28] [29] . However, point mutation of JAK2 in ALL is very rare 30, 31 . We examined for JAK2 mutations at "hot-spots" (exons 12 and 14)
18, [27] [28] [29] in these 7 cases of ALL with 9p UPD in which deletion of INK4A was not detected. We found no mutations of JAK2 in these cases. Another unidentified gene(s) in the region may be mutated in these cases.
In this study, we found that absence of gain of chromosomes 17 and 18 had an adverse impact on the prognosis of children with HD-ALL. Another large-scale study found that gain of chromosome 17 was associated with a better prognosis in HD-ALL 32 . Although this previous study reported that gain of chromosomes 4 and10 was also associated with a better prognosis, our study showed that change in number of these chromosomes did not have an impact on prognosis. Even though the size of our study is relatively large, it might not be able to detect some important factors associated with survival because the number of cases of this ALL subtype enrolled in our study was too small or advances in treatment of pediatric ALL may have eliminated several factors that previously influenced prognosis.
One of the limitation of SNP-chip analysis is that it cannot detect balanced translocations which are common abnormalities in ALL since this technique can only detect allelic dosage. In our correlation study of genomic abnormalities, a strong correlation was found between abnormalities involving 12p and 21q as described above. This, in part, reflected translocations of chromosome 12p and 21q (ETV6/RUNX1 fusion). Another correlation that we found between p16Del (on 9p) and deletion of 20q, may reflect dic (9;20)(p13;q11) 33, 34 . These strong correlations of gains or loss of genetic materials may, therefore, sometimes suggest unbalanced translocations in ALL. Combination of SNP-chip and karyotyping will be a very strong technique to examine all genomic abnormalities in malignant cells.
Molecular allelokaryotyping of a series of 399 pediatric ALL samples has defined the range of genetic changes that occur in childhood ALL, including those associated with a poor prognosis. SNP-chip analysis is a novel technique that allows a thorough interrogation of the genome in ALL and identification of clinically significant subgroups of patients. 
Authors' contributions:
Norihiko Kawamata designed this study, performed experiments, analyzed the data and wrote the paper. Seishi Ogawa designed this study, performed experiments, analyzed the data and wrote the paper. Martin Zimmermann analyzed the data and wrote the paper. Motohiro Kato analyzed the data. Masashi Sanada performed experiments and analyzed the data. Kari Hemminki analyzed the data and wrote the paper. Go Yamatomo performed experiments and analyzed the data. Yasuhito Nannya performed experiments and analyzed the data. Rolf Koehler analyzed the data and wrote the paper. Thomas Flohr analyzed the data. Carl W. Miller analyzed the data. Jochen Harbott analyzed the data. Wolf-Dieter Ludwig analyzed the data and wrote the paper. Martin Stanulla analyzed the data. Martin Schrappe designed this study and wrote the paper. Claus R. Bartram designed this study, analyzed the data and wrote the paper. H. Phillip Koeffler designed this study, analyzed the data and wrote the paper. .
The authors declare no competing financial interests. only.
For only.
